Chromosome Instability in Patients with Chronic Renal Failure

Lialiaris, Theodoros; Mavromatidou, Polyxeni; Digkas, Evangelos; Passadaki, Theoktisti; Mpountoukas, Panagiotis; Panagoutsos, Stylianos; Vargemezis, Vassilios

doi:10.1089/gtmb.2009.0109

Cited by 16 publications

(10 citation statements)

References 45 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with ESRD, genomic damage has been shown by numerous biomarkers, such as the analysis of sister chromatid exchange and chromosomal aberrations (Cengiz et al, 1988, Lialiaris et al, 2010, MN frequency (Stopper et al, 1999;Sandoval et al, 2010), comet assay in peripheral lymphocytes (Stopper et al, 2001;Kobras et al, 2006;Aykanat et al, 2011), 8-hydroxy 2-deoxyguanosine content in leukocytes (Tarng et al, 2004), and mitochondrial DNA deletions in skeletal muscle tissue and hair follicles (Liu et al, 2001). Our results also confirmed that patients with ESRD exhibit increased levels of genomic damage, as measured by the MN assay.…”

Section: Discussionsupporting

confidence: 82%

Relationship Between Genomic Damage and Clinical Features in Dialysis Patients

Güven

Altıparmak

Trabulus

et al. 2013

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Patients with end-stage renal disease display enhanced genomic damage. We investigated the presence of genomic damage in the peripheral lymphocytes by using the micronucleus (MN) test and the factors associated with the MN frequency in hemodialysis (HD) and peritoneal dialysis (PD) patients. We studied 121 dialysis patients (60 HD and 61 PD) and 129 age- and gender-matched healthy controls. The MN analysis, used as a biomarker of chromosomal/DNA damage, was performed in peripheral lymphocytes by the cytokinesis-block method. Univariate analysis showed a significantly higher MN frequency in all patients in comparison with the controls (7.6% ± 0.3% vs. 4.9% ± 0.2%, respectively, p<0.001). Significantly higher frequency of MN was observed in both HD and PD patients compared to controls (7.7% ± 0.5% vs. 4.9% ± 0.2%, p<0.001 and 7.5% ± 0.5% vs. 4.9% ± 0.2%, p<0.001, respectively). Multivariate analysis was performed, and it showed that the low-density lipoprotein level was the only independent determinant of increasing MN frequency in our patients (β=0.16, t=2.172, p<0.05). There is no significant difference in terms of genomic damage between two dialysis modalities, which suggests that PD may not be a more reliable choice in terms of genomic damage.

show abstract

Section: Discussionsupporting

confidence: 82%

Relationship Between Genomic Damage and Clinical Features in Dialysis Patients

Güven

Altıparmak

Trabulus

et al. 2013

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

“…The biomarkers used in these studies were micronuclei in peripheral blood lymphocytes (PBL) (7,(25)(26)(27) and BEC (9), chromosome aberrations and sister chromatid exchanges (28,29), and DNA strand breaks (comet assay) (26-28, 30, 31). The only reports regarding children with CKD were our recent studies using the MN and comet assays in PBL of children (15,16).…”

Section: Resultsmentioning

confidence: 99%

Micronuclei and other nuclear anomalies in buccal epithelial cells of children with chronic kidney disease

Aykanat

Demircigil

Buyan

et al. 2016

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

The objective of this study was to reveal the likely genomic instability in children with chronic kidney disease (CKD) using micronucleus (MN) assay on buccal epithelial cells (BEC). We investigated the frequencies of micronuclei and other nuclear anomalies, such as nuclear buds, binucleated cells, condensed chromatin, and karyorrhectic and pyknotic cells in BEC. Children with CKD were grouped as follows: children in the pre-dialysis (PreD) stage (N=17), children on regular haemodialysis (HD) (N=14), and children who have undergone transplantation (Tx) (N=17). As a control group, twenty age-and gender-matched healthy children were selected. The MN frequency in BEC of all groups of children with CKD was significantly elevated (5-to 7-fold) as compared to the control group (p<0.001). In contrast, the frequencies of nuclear buds were not significantly higher in the study groups compared to the control group. The frequencies of binucleated cells and condensed chromatin cells were significantly higher in all subgroups of children with CKD relative to the control group (p<0.001). Our results show that the BEC of pediatric PreD, HD, and Tx patients with CKD display increased cytogenetic, cytokinetic, and cytotoxic effects. They also point to the sensitivity and usefulness of the BEC MN assay in the assessment of genetic susceptibility of patients with CKD.

show abstract

“…The method used was the study of Sister Chromatid Exchanges (SCEs). IFO is a powerful and effective drug performing exceptionally in anticancer therapy, on the other hand it induces chromatid fragility and genotoxicity even in healthy tissue cells (Chen et al 2007;Hansen et al 2007;Lialiaris et al 2010a). As previously stated, Mesna can help to avoid haemorrhagic cystitis induced following administration of IFO.…”

Section: Introductionmentioning

confidence: 92%

“…Employing this method, contributes appreciably in testing efficiently and improving chemotherapeutic techniques. The SCEs method is a notably more sensitive method than the one based on chromosomal aberrations, as chromosome damage is more accurate to detect even in low concentrations of the genotoxic factor (Yilmaz et al 2009, Lialiaris et al 2009a, Lialiaris et al 2010b, Mamur et al 2012, Istifli and Topakt 2012. With respect to the other two cytogenetic markers used, namely PRI and MI, they are both valuable markers of the cytostatic and cytotoxic action of various factors, including the chemotherapeutic ones (Das 1988;Maskaleris et al 1998;Fousteris et al 2006;Lialiaris et al 2009a;Mourelatos et al 2012).…”

Section: Introductionmentioning

confidence: 99%

The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study

et al. 2013

View full text Add to dashboard Cite

Ifosfamide (IFO) is an alkylating nitrogen mustard, administrated as an antineoplasmic agent. It is characterized by its intense urotoxic action, leading to hemorrhagic cystitis. This side effect of IFO raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect. IFO and Mesna were administrated separately on rabbit's lymphocytes in vivo, which were later developed in vitro. Cytogenetic markers for sister chromatid exchanges (SCEs), proliferation rate index (PRI) and Mitotic Index were recorded. Mesna's action, in conjunction with IFO reduces the frequency of SCEs, in comparison with the SCEs recordings obtained when IFO is administered alone. In addition to this, when high concentrations of Mesna were administered alone significant reductions of the PRI were noted, than with IFO acting at the same concentration on the lymphocytes. Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.

show abstract

Chromosome Instability in Patients with Chronic Renal Failure

Abstract: This study illustrates increased genetic instability in patients with CRF. These results could also be of a great importance in early diagnosis to prognosticate a possible generation of neoplasm in the future.

Cited by 16 publications

References 45 publications

Relationship Between Genomic Damage and Clinical Features in Dialysis Patients

Relationship Between Genomic Damage and Clinical Features in Dialysis Patients

Micronuclei and other nuclear anomalies in buccal epithelial cells of children with chronic kidney disease

The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study

Contact Info

Product

Resources

About